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CD8/ cytotoxic T lymphocytes (CTL) have an established role in anti-viral immunity, but whether CTL function efficiently
in the brain remains unclear. In particular, virus-infected neurons, which express only low levels of MHC class I antigens
and are resistant to the induction of apoptosis, could constitute a relatively intractable CTL target. We have used immune
lymphocytes adoptively transferred into the CSF to protect naive mice against an intracerebral infection with influenza
A/WSN, a virus that infects neurons in the brain parenchyma and causes a lethal encephalitis. After in vitro restimulation,
heterotypically immune spleen cells protected against A/WSN encephalitis in an H-2-restricted, CD8-dependent, CD4-
independent manner. Adoptively transferred CTL clones were also protective. Homotypically immune spleen cells additionally
mediated CD8-independent, H-2-unrestricted protection, probably due to the generation of A/WSN-specific plasma cells
from memory B cells during in vitro restimulation. Thus after in vitro restimulation, either CTL or B cells adoptively transferred
into the CSF protected against an acutely lethal intracerebral virus infection. q 1997 Academic Press
INTRODUCTION acute encephalitis. Adoptively transferred CTL do protect
against an acute encephalitis due to the murine coronavi-
Adoptive cell transfers, in vivo lymphocyte depletions, rus JHM, but it is unclear to what extent this depends
and genetically immunodeficient mice have all demon- upon the elimination of infection from glial cells rather
strated that CD8/ T cells are a major component of than neurons (Sussman et al., 1989; Yamaguchi et al.,
anti-viral immunity (Doherty et al., 1992). Acquired T cell 1991; Stohlman et al., 1995).
deficiencies in man are often complicated by a pathologi- We have explored protection against infection with the
cal increase in the replicative and tumorigenic activity of neurovirulent influenza virus A/WSN (Stuart-Harris, 1939).
persistent virus infections, and adoptive CTL transfer has As well as being a common cause of epidemic respira-
in these cases been used successfully to control sys- tory disease, the type A influenza viruses are a suspected
temic disease (Rooney et al., 1995; Walter et al., 1995). factor in a variety of neuropsychiatric conditions (Ra-
T cell deficiencies are also associated with opportunistic venholt and Foege, 1982; Yolken and Torrey, 1995). Fowl
viral diseases of the central nervous system (Johnson,
influenza viruses readily become neurovirulent in other
1982). Infections in this site present particular obstacles
species (Bonin and Scholtissek, 1983; Kawaoka, 1991)
to immune clearance, since neurons may express insuffi-
and remain a potential source of new neurovirulent epi-
cient levels of the MHC class I molecules required for
demics in man (Webster et al., 1982). In contrast to non-
recognition by CTL (Joly et al., 1991). Neurons are also
neurovirulent strains, which infect only the ependymalresistant to the induction of apoptosis (Griffin et al., 1994),
cells after intracerebral inoculation and are relatively in-which is a major mechanism of anti-viral CTL immunity
nocuous (Mims, 1960), A/WSN spreads progressivelyin extracerebral sites (Berke, 1994). CTL can apparently
throughout the brain parenchyma, where it infects neu-clear virus infections from neurons (Simmons and
rons, but not other cell types (Takahashi et al., 1995),Tscharke, 1992; Planz et al., 1993; Stevenson et al., 1996),
and causes a lethal encephalitis.but this may occur more slowly than in extracerebral
Neutralizing antibodies protect against homotypic in-sites (Oldstone et al., 1986; Ahmed et al., 1987). Any delay
fluenza virus infections in both the lung (Virelizier, 1975;in CTL effectiveness could have fatal consequences in
Palladino et al., 1995) and the brain (Doherty and Ger-
hard, 1981). Although antibodies do not protect against
heterotypic influenza A viruses, primed CTL provide a1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (901) 495-3107. degree of subtype-cross-reactive immunity (Effros et al.,
2 Present address: Department of Clinical Neuroscience, Charing 1977; Zweerink et al., 1977; Liang et al., 1994), and adop-
Cross and Westminster Medical School, Fulham Palace Road, London, tively transferred CTL protect naive mice against respira-UK.
tory influenza virus infections (Yap et al., 1978; Taylor3 Present address: Department of Immunology, St. Mary’s Hospital
Medical School, Norfolk Place, London, UK. and Askonas, 1986). Heterotypic immunity also protects
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against A/WSN encephalitis in a CD8-dependent manner leted by brief centrifugation. Fivefold dilutions of the su-
pernatant were made in MEM (Life Technologies, Pais-(Stevenson et al., 1996). Here we have used adoptively
transferred immune lymphocytes to protect naive mice ley, UK), supplemented with penicillin (60 mg/ml), strepto-
mycin (100 mg/ml), glutamine (2 mM), and BSA (1%).against the lethal encephalitis due to intracerebral influ-
enza A/WSN infection. We have thus examined the thera- Triplicate 150-ml aliquots of each dilution were mixed
with a further 50 ml of MEM containing 2 1 104 freshlypeutic potential of CTL transferred into the CSF in com-
batting an acute, severe neuronal infection. trypsinized MDCK cells. After 48 hr growth at 377, the
cultures were frozen and thawed once to disrupt infected
cells. Virus growth was detected by mixing 100 ml ofMATERIALS AND METHODS
each culture with chicken red cells (final concentration
Mice
0.5%) (Serotec, Kidlington, UK) and allowing 30 min for
agglutination at room temperature. A dilution was consid-C57BL/10 (I-Ab, Db, Kb) and C57BL/10.A (I-Ak, Dd, Kk)
mice were bred at Harlan UK Ltd (Bicester, UK) and were ered positive for virus if red cell agglutination was seen
in at least two of the three replicate wells. Negative ag-kept under standard Home Office-approved conditions
at the Biomedical Services Unit, John Radcliffe Hospital glutination at the lowest dilution (25 ml of the total 1-ml
organ homogenate per well) was designated as 1 titer(Oxford). Mice were used at 6–10 weeks of age, matched
for age and sex within each experiment. There was no unit, the lower limit of assay sensitivity.
difference in experimental outcome between males and
ELISAfemales or across the age range stated.
Influenza A/WSN was purified from infectious allan-Intracerebral injections
toic fluid by sucrose density gradient centrifugation
Intracerebral injections were performed with the mice (Barrett and Inglis, 1985) and coated overnight at 47
immobilized in a stereotactic frame. Mice were anae- onto Nunc Polysorb immunoplates (Life Technologies)
sthetised for the procedure with Hypnorm (Janssen Phar- using 400 ng/well virus in sodium bicarbonate (50 mM,
maceuticals, Wantage, UK) and Hypnovel (Roche, Wel- pH 9.7)/sarkosyl (0.025%) buffer. All subsequent steps
wyn Garden City, UK). Virus was inoculated into the lat- were carried out at room temperature. Coated plates
eral cerebral ventricle (coordinates relative to bregma: were washed four times with 0.05% Tween in ddH2O,
posterior, 0.5 mm; left lateral, 0.8 mm; depth, 1.7 mm) in and nonspecific protein binding was blocked by incu-
a volume of 5 ml unless stated otherwise. The skin was bation for 20 min with 2% BSA in PBS/Tween (0.05%)/
sutured after a slow withdrawal of the needle and all EDTA (1 mM). After two further washes, duplicate five-
mice made an uneventful recovery from the operation. fold dilutions of culture supernatants were incubated
Lymphocytes were injected into the same site by the for 1 hr, followed by five washes. Horseradish peroxi-
same procedure 24 hr later. dase-coupled goat anti-mouse Fcg (Sigma Chemical
Co., Poole, UK) was then incubated for 1 hr, followed
Viruses by a further five washes. O-phenylenediamine dihydro-
chloride (1 mg/ml) (Sigma) was used as the peroxidaseInfluenza viruses A/WSN (H1N1), A/X31 (H3N2), and
substrate, the reaction was terminated with 3 M HCl,A/NT/60/68 (H3N2) were grown in embryonated hens’
and the OD was read at 492 nm.eggs by standard protocols (Barrett and Inglis, 1985).
Aliquots of infectious allantoic fluid were kept at 0807
Restimulation of CTLand thawed only once before being discarded. The LD50
for a 5-ml intracerebral inoculation of A/WSN was a Spleen cells (106/ml), pooled from three or more mice
1/105 dilution of allantoic fluid for both C57BL/10 and immunized intranasally with influenza virus 1–3 months
C57BL/10.A mice. Three hundred LD50 , equivalent to previously, were restimulated with virus-infected feeder
0.006 HAU, was used as the standard intracerebral chal- cells (3 1 105/ml) in 40-ml cultures. Feeder spleen cells
lenge. Without immune rescue, this challenge was uni- were prepared from syngeneic naive mice by infection
formly lethal. For intranasal immunization with influenza with influenza A/WSN, A/X31, or A/NT/60/68 (all at 2 PFU/
A/WSN, mice were briefly anaesthetized with ether and cell) for 1 hr at 377 in RPMI, irradiation (20 Gy), and two
given 0.01 HAU of virus (equivalent to 0.1 LD50 by this washes in RPMI-supplemented 2-mercaptoethanol (50
route) in 30 ml PBS/BSA (1%). mM), penicillin (60 mg/ml), streptomycin (100 mg/ml),
glutamine (2 mM) (Life Technologies), and 10% FCS
Virus titers in infected brains
(Globepharm, Esher, UK) (complete medium). Cells were
used for adoptive transfer or in vitro assay after 5 daysReplication-competent A/WSN virus was recovered by
Dounce homogenization of the brain in 1 ml of ice-cold of culture in complete medium at 377 with 5% CO2 .
To derive CTL clones, A/WSN-primed, A/X-31-restimu-PBS/BSA (1%). The homogenate was frozen and thawed
once to disrupt infected cells, and solid debris was pel- lated spleen cells were further restimulated in vitro using
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irradiated feeder cells pulsed with 1 mM ASNENMETM The efficacy of depletion was assessed by flow cyto-
metric analysis with directly conjugated anti-CD4 (KT6-peptide (the immunodominant, H-2Db-restricted nucleo-
protein 366–374 epitope of influenza A/X31 and influenza PE, Serotec) and anti-CD8 (KT15-FITC, Serotec) for T
cells, and rat anti-B220 (RA3-6B2, Serotec) plus mouse-A/WSN) plus recombinant IL-2 (25 ng/ml final concentra-
tion, R&D systems, Abingdon, UK). CTL were cloned by adsorbed, biotinylated rabbit anti-rat IgG (Dako, High Wy-
combe, UK) plus streptavidin-FITC (Sigma) for B cells.limiting dilution at the third in vitro passage using ASN-
ENMETM-pulsed feeder cells (2 1 105 cells/200 ml well) Lymphocyte subset depletion was 95% complete in
each case (not shown).and IL-2. Clones were taken from responder T cell dilu-
tions with fewer than 20% wells positive for T cell growth
and were maintained by a weekly restimulation with pep-
RESULTS
tide-pulsed, irradiated syngeneic feeder cells and IL-2.
The clone F5, which recognizes the A/NT/60/68 nucleo- Protection after adoptive transfer by different routes
protein peptide ASNENMDAM, but not ASNENMETM
(Townsend et al., 1984), was kindly provided by Dr. V. Influenza-specific immune spleen cells were gener-
ated by priming mice intranasally with influenza A/WSN,Cerundolo (Institute of Molecular Medicine, John Rad-
cliffe Hospital, Oxford, UK). and 1–3 months later restimulating in vitro immune
spleen cells, pooled from two to four mice, with influenza
CTL assay A/X31-infected feeder cells. The restimulated spleen
cells were then adoptively transferred into naive mice
EL-4 (H-2b) target cells were labeled with 51Cr (100
that had been inoculated with 300 LD50 influenza A/WSNmCi, Amersham International, Amersham, UK) for 1 hr at
into the lateral cerebral ventricle 1 day earlier. Intrave-
377 and washed once. They were then either incubated
nously transferred immune spleen cells (20 1 106 cells
with complete medium alone, pulsed with 1 mM ASN-
in 200 ml) were relatively ineffective in protecting against
ENMETM peptide, or infected with A/WSN (5 PFU/cell)
A/WSN encephalitis (2/10 mice survived). In contrast, the
in RPMI. After 1 hr at 377, the target cells were washed
same immune spleen cells, when adoptively transferred
twice in complete medium. Supernatants were harvested
into the lateral cerebral ventricle (106 cells in 30 ml), pro-
for scintillation counting after a further 4 hr of culture
tected 7/7 mice. Restimulation in vitro was necessary for
with the effector cells. Targets with effector cells were
protection against encephalitis; 0% (n  6) of mice given
measured in duplicate and control targets with Triton
intracerebral A/WSN survived after the intracerebral
or medium alone were measured in quadruplicate. The
transfer of 5 1 106 unstimulated spleen cells from
percentage of specific lysis was calculated as 1001 (re-
A/WSN-primed mice.
lease by CTL 0 release by targets alone)/(release with
Triton 0 released by targets alone). 51Cr release from
Protection by CTL lines specific for different influenzathe targets alone was 5– 15% of release with Triton.
virus strains
In vitro depletions of lymphocyte subsets
The efficacy of different influenza virus strains in elic-
iting protective heterotypic immunity correlates with theLymphocyte subsets were depleted from immune
spleen cell pools either before or after in vitro restimula- efficacy of the different strains in priming anti-viral CTL
(Webster and Askonas, 1980; Stevenson et al., 1996). Totion, using the same protocol in each case. To deplete
T cells subsets, spleen cells were washed twice in RPMI establish whether this also applied to protection against
encephalitis by adoptive transfer, we used different influ-and an anti-CD4 (YTS191.1.2 and YTA3.1.2) or anti-CD8
(YTS169.4 and YTS156) monoclonal antibody mixture (all enza A virus strains both to prime mice in vivo and to
restimulate primed spleen cells in vitro. The immunerat IgG2b antibodies, final concentration 40 mg/ml) was
added for 10 min on ice. Guinea pig complement (Sigma) spleen cells generated by in vitro restimulation were
compared by in vivo protection against A/WSN encepha-was then added (20% final concentration) and the cells
were incubated at 377 for 45 min. B cells were depleted litis and by in vitro A/WSN-specific cytotoxicity (Table 1).
Intranasal immunization with influenza A/NT/60/68using sheep anti-mouse Ig-coated Dynabeads (Dynal,
Wirral, UK) according to the manufacturer’s instructions. (H3N2) (40 HAU) was less effective than immunization
with influenza A/X31 (H3N2) (20 HAU) in generating bothSpleen cells were washed three times in RPMI to remove
unbound immunoglobulin and incubated with washed protective and cytotoxic anti-viral spleen cells. This sug-
gested that immune CTL were responsible for hetero-beads (5 1 107 cells/ml and 15 1 107 beads/ml) at 47 for
30 min with constant mixing. The unbound cells were typic protection against encephalitis after adoptive trans-
fer. However, intranasal priming with A/X31 generatedincubated a second time for 30 min at 47 using 1/5 the
initial bead concentration. After each depletion, the re- less protective spleen cells than did priming with A/WSN
(H1N1) (0.01 HAU), despite eliciting greater in vitro anti-maining cells were washed twice in complete medium
before use. A/WSN cytotoxicity. This suggested that other A/WSN-
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TABLE 1
In Vitro Cytotoxicity and in Vivo Protection by Different Influenza Virus-Specific Immune Spleen Cells
Source of restimulated spleen cells Anti-A/WSN cytotoxicity
(E:T ratio)
Priming virus Restimulating virus Anti-A/WSN protection
(in vivo) (in vitro) 30:1 6:1 (% Survivors)
A/WSN A/WSN 23a 11 100
A/X31 A/WSN 42 37 83
A/X31 A/X31 37 26 67
A/NT/60/68 A/WSN 10 6 17
A/NT/60/68 A/NT/60/68 9 2 33
Note. Mice were primed intranasally, and 1–3 months later spleen cells were pooled from 3 equivalent mice and restimulated in vitro as indicated.
After 5 days of culture, each pool of spleen cells was tested for in vitro anti-A/WSN cytotoxicity and for in vivo protection of 6 mice (in 2 trials) given
300 LD50 A/WSN virus into the lateral cerebral ventricle 1 day earlier. Net % specific lysis  (% specific lysis of A/WSN-infected target cells) 0
(% specific lysis of uninfected target cells). Specific lysis of uninfected target cells did not exceed 15%.
a Net percentage of specific lysis.
specific (homotypic) effectors could also protect against the same protocol (Table 3). Three separate CD8/ CTL
clones, all specific for the immunodominant viral nucleo-encephalitis after adoptive transfer.
To further compare homotypic and heterotypic protec- protein epitope (Townsend et al., 1984), gave H-2-re-
stricted protection which depended upon CTL viability,tion, A/WSN-primed spleen cells, pooled from three or
four mice, were restimulated in vitro with either A/WSN- whereas an irrelevant activated CTL clone was ineffec-
tive. The in vivo anti-viral activity of the anti-A/WSN clonesprimed or A/X31-primed feeder cells. Thus there was
an equivalent frequency of primed lymphocytes before was confirmed by intracerebral virus titers after cell
transfer (Table 4). The protective clones all achieved arestimulation in each case. After either restimulation, pro-
tection was critically dependent upon transferring an ad- significant H-2-restricted reduction in intracerebral virus
titer, while the irrelevant CTL clone had no effect. Againequate number (5 1 105) of immune lymphocytes; 105
cells protected fewer than 40% of A/WSN-infected mice we found that intravenous T cell inoculation was much
less efficient than intracerebral inoculation; the A/WSN-and 2 1 104 cells gave no effective protection (not
shown). To identify the important T cell subsets, the specific clones (20 1 106 cells in 200 ml) each protected
fewer than 20% of A/WSN-challenged mice (n 10) whenspleen cells were depleted with anti-CD4 or anti-CD8
antibodies; to distinguish the cells directly mediating pro- given intravenously.
tection from those contributing to restimulation, this was
done either before or after in vitro restimulation. TABLE 2
Protection against A/WSN Encephalitis by
Heterotypic protection against A/WSN encephalitis Heterotypically Immune Spleen Cells
After restimulation with A/X31-infected feeder cells, im- Recipient Donor cells % Survivors n
mune protection was H-2-restricted and was abolished
C57BL/10 Undepleted 73 26by the depletion of CD8/ T cells, either before or after
C57BL/10 CD4 0 depleted (Day 0) 82 10restimulation (Table 2). The depletion of CD4/ T cells
C57BL/10 CD8 0 depleted (Day 0) 0 5after restimulation had no effect on the capacity of the
C57BL/10 CD4 0 depleted (Day 5) 81 16
immune spleen cell population to protect against en- C57BL/10 CD8 0 depleted (Day 5) 9 11
cephalitis, implying that these cells had no significant C57BL/10.A Undepleted 0 5
effector role after adoptive transfer. The depletion of
Note. Spleen cells were pooled from 3–4 C57BL/10 mice given intra-CD4/ T cells before restimulation also had no effect on
nasal influenza A/WSN 1–3 months earlier and were restimulated inprotection; this indicated that under the in vitro conditions
vitro for 5 days with A/X-31-infected feeder cells. Spleen cells were
used, the restimulation of memory CTL was independent depleted with anti-CD4 or anti-CD8 antibodies plus complement, either
of help from CD4/memory T cells. Thus a heterotypically before (Day 0) or after (Day 5) restimulation. Undepleted cells were
treated with complement alone. 5 1 105 restimulated spleen cells wereimmune population of splenic lymphocytes mediated H-
inoculated into the lateral cerebral ventricle of mice given 300 LD502-restricted, CD8-dependent, CD4-independent protec-
influenza A/WSN into the same site 1 day earlier. Results were pooledtion against A/WSN encephalitis.
from 3 trials (n  total number of mice). CD8 depletion either before
To establish that adoptively transferred CTL alone (P 0.005 by chi-square test) or after (P 0.0005) restimulation signifi-
were sufficient for protection, A/WSN-specific CTL clones cantly reduced protection, whereas CD4 depletion had no significant
effect.were used to protect naive mice against encephalitis by
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TABLE 3 TABLE 5
Protection against A/WSN Encephalitis by CD8/ T Cell Clones Protection against A/WSN Encephalitis by
Homotypically Immune Spleen Cells
CTL clone adoptively transferred
Percentage of
Recipient Donor cells survivors nRecipient Cell number 1.2 1.3 1.8 F5
C57BL/10 5 1 105 82a (17) 100 (4) 80 (15) 0 (5) C57BL/10 Undepleted 89 27
C57BL/10 CD4 0 depleted (Day 0) 67 12C57BL/10 1 1 105 0 (4) 50 (4) 100 (4) ND
C57BL/10 2 1 104 ND 25 (4) 50 (4) ND C57BL/10 CD8 0 depleted (Day 0) 45 11
C57BL/10 CD4 0 depleted (Day 5) 92 12C57BL/10 5 1 105 (fixed) 0 (5) 0 (4) 0 (4) ND
C57BL/10.A 5 1 105 0 (5) 0 (4) 0 (5) 0 (5) C57BL/10 CD8 0 depleted (Day 5) 58 12
C57BL/10.A Undepleted 82 11
Note. CTL clones were derived from A/WSN-immune C57BL/10
spleen cells. Five days after in vitro restimulation, CTL were inoculated Note. Spleen cells were pooled from 3–4 C57BL/10 mice given intra-
nasal influenza A/WSN 1–3 months earlier and were restimulated ininto the lateral cerebral ventricle of mice given 300 LD50 influenza A/
WSN into the same site 1 day earlier. Clones 1.2, 1.3, and 1.8 recognize vitro for 5 days with A/WSN-infected feeder cells. Spleen cells were
depleted with anti-CD4 or anti-CD8 antibodies plus complement, eitherthe H-2Db-restricted A/WSN nucleoprotein epitope, whereas clone F5
is specific for the equivalent sequence of influenza A/NT/60/68 and before (Day 0) or after (Day 5) restimulation. Undepleted cells were
treated with complement alone. 5 1 105 restimulated spleen cells weredoes not recognize A/WSN-infected cells. CTL were fixed prior to inocu-
lation where indicated in PBS/glutaraldehyde (0.05%) for 1 min followed inoculated into the lateral cerebral ventricle of mice given 300 LD50
influenza A/WSN into the same site 1 day earlier. Results were pooledby quenching in PBS/lysine (0.2 M) and 2 washes in RPMI. Each figure
gives the percentage of mice surviving and in parentheses the total from 5 trials (n  total number of mice). As with heterotypic immunity,
CD8 depletion either before (P  0.01 by chi-squared test) or afternumber of mice inoculated. Results were pooled from 4 trials. ND, not
done. (P  0.04) restimulation significantly reduced protection while the re-
duction in protection due to CD4 depletion before restimulation wasa Percentage of survivors.
not significant (P  0.09). However, the difference in survival between
CD4 and CD8 depletions was much less marked than with heterotypic
immunity and the H-2 mismatched protection was not significantly lessHomotypic protection against A/WSN encephalitis
than the H-2-matched protection.
In contrast to the CD8-dependent protection after re-
stimulation with influenza A/X31, the protection achieved
after the restimulation of equivalent A/WSN-primed In vitro antibody production was much less prominent
after restimulation with A/X31-infected feeders. The low-spleen cells with influenza A/WSN was only partially re-
duced by anti-CD8 treatment (Table 5) and was not H- level antibody measured in this case was probably di-
rected against cross-reactive but nonneutralizing internal2-restricted. This additional protection was not due to
residual CTL activity in the A/WSN-restimulated popula- viral antigens; anti-A/WSN hemagglutination inhibiting
activity (Barrett and Inglis, 1985) was detectable in cul-tion, since the abrogation of anti-A/WSN cytotoxicity by
CD8/ T cell depletion was equivalent with either restim- ture supernatants after restimulation with A/WSN (mean
{ SEM log2 titer from six cultures  2.5 { 0.2) but notulation (Fig. 1). Adoptively transferred antibody can pro-
tect against A/WSN encephalitis (Doherty and Gerhard, with A/X31 (mean { SEM log2 titer from six cultures 
0.0 { 0.0).1981), so A/WSN-specific B cells, restimulated in vitro by
A/WSN (H1N1) but not by influenza A/X31 (H3N2), Anti-Ig depletion of the immune spleen cells before
in vitro restimulation prevented the production of anti-seemed the most likely non-CD8 cell-type to be contribut-
ing to protection. Anti-A/WSN IgG could be detected in A/WSN IgG, abolished the H-2-unrestricted protection,
and considerably reduced the protection afforded toculture supernatants after in vitro restimulation (Fig. 2).
TABLE 4
Reduction in Intracerebral Virus Titers by CTL Clones
CTL clone adoptively transferred
Recipient 1.2 1.3 1.8 F5 None
C57BL /10 3.3 { 0.6 a 1.6 { 0.9 0.8 { 0.8 6.3 { 0.0 6.6 { 0.0
C57BL /10.A 6.1 { 0.5 6.1 { 0.2 6.8 { 0.3 6.1 { 0.2 6.1 { 0.2
Note. C57BL/10 CTL clones were inoculated, 5 days after in vitro restimulation, into the lateral cerebral ventricle of mice given 300 LD50 influenza
A/WSN into the same site 1 day earlier. Brains were assayed for infectious virus 2 days after clone transfer. Each value shows the mean { SEM
of titers from 3 separate mice. Each of the A/WSN-specific clones caused a significant reduction in virus titer in H-2-matched mice (P  0.007 by
paired t test), whereas there was no reduction in H-2-mismatched mice or with the irrelevant F5 clone.
a log10 virus titer.
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ously effective with all populations depleted of Ig/
cells after restimulation. Since a consistent number (5
1 105) of restimulated spleen cells was transferred
after each depletion (to account for the nonspecific
loss of cells after additional manipulations) the re-
moval of nonprotective cells would have led to a higher
number of protective lymphocytes being transferred.
Protection against A/WSN infection in the brain
parenchyma
Intracerebral A/WSN infection spreads rapidly from the
CSF into the brain parenchyma (Mims, 1960; Takahashi
et al., 1995). Thus the protection achieved by cells inocu-
lated into the CSF 1 day after virus infection suggested
that these cells cleared virus from both the ependymal
cells lining the CSF spaces and infected neurons in the
brain parenchyma. Large volume (5 ml) intracerebral in-
jections inevitably spill into the CSF (Mims, 1959). To
determine whether cells inoculated into the CSF also
protected against A/WSN inoculated directly into the
brain parenchyma, virus (100 LD50) was inoculated into
FIG. 1. Effect of in vitro lymphocyte depletions on the cytotoxic activity
of A/WSN-primed spleen cells. Spleen cells were pooled from 5 mice,
1– 3 months after intranasal immunization with influenza A/WSN. Deple-
tion was performed either before (Day 0) or after (Day 5) in vitro restimu-
lation with A/WSN- or A/X31-infected feeder cells as indicated. Net %
specific lysis  (% specific lysis of target cells pulsed with 1 mM
ASNENMETM peptide) 0 (% specific lysis of untreated target cells).
Specific lysis of target cells alone did not exceed 10%.
syngeneic mice (Table 6) without affecting CTL activity
(Fig. 1). Thus B cells were responsible for the H-2-
mismatched protection and also contributed signifi-
cantly to the homotypic protection of H-2-matched
mice. Surprisingly, the same anti-Ig treatment after re-
stimulation had no significant effect on protection (Ta-
ble 6). The depletion of B220hi cells achieved by anti-
Ig treatment was numerically equivalent if performed
either before or after in vitro culture (not shown), so
the failure of anti-Ig treatment after restimulation to
abolish protection suggested that the protective cells,
in contrast to their Ig/ precursors, expressed only low FIG. 2. Specific IgG production by A/WSN-primed spleen cells during
in vitro restimulation. Spleen cells were pooled from 3 mice, 1–3levels of surface Ig. The efficacy of these cells alone
months after intranasal immunization with influenza A/WSN. Depletionin protecting against encephalitis was confimed by de-
was performed prior to in vitro restimulation with influenza virus-in-pleting, after in vitro culture, CD4 and CD8 T cells to-
fected feeder cells as indicated. After 5 days of culture, supernatants
gether with cells expressing surface Ig (Table 6). This were assayed for anti-A/WSN IgG and IgM by ELISA. Means and SEMs
failed to diminish either H-2-matched or H-2-mis- of 4 supernatants per group are shown, normalized by reference to a
standard immune serum.matched protection. Indeed, protection was conspicu-
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TABLE 6
Protection against A/WSN Encephalitis by Immune B Cells
Percentage of
Donor Recipient Depletion Time survivors n
C57BL/10 C57BL/10 Anti-Ig Day 0 33 12
C57BL/10 C57BL/10 Anti-Ig Day 5 80 5
C57BL/10 C57BL/10 Anti-Ig/CD4/CD8 Day 5 100 5
C57BL/10 C57BL/10.A Anti-Ig Day 0 0 13
C57BL/10 C57BL/10.A Anti-Ig Day 5 80 5
C57BL/10 C57BL/10.A Anti-Ig/CD4/CD8 Day 5 80 5
C57BL/10.A C57BL/10 Anti-Ig/CD4/CD8 Day 5 100 6
C57BL/10.A C57BL/10.A Anti-Ig/CD4/CD8 Day 5 100 5
Note. Spleen cells were pooled from 3–4 C57BL/10 or C57BL10.A mice given intranasal influenza A/WSN 1–3 months earlier and were restimulated
in vitro for 5 days with A/WSN-infected feeder cells. Spleen cells were depleted with anti-Ig magnetic beads, either before (Day 0) or after (Day 5)
restimulation. Where indicated, anti-Ig depletion was followed by CD4 and CD8 depletions using monoclonal antibodies and complement as before.
5 1 105 restimulated spleen cells were inoculated into the lateral cerebral ventricle of mice given 300 LD50 influenza A/WSN into the same site 1
day earlier. Results were pooled from 4 trials (n  total number of mice). Anti-Ig depletion at Day 0 caused less reduction in H-2-matched than in
H-2-mismatched protection (P  0.04 by chi-squared test).
the anterior caudoputamen of naive mice in 0.5 ml (coor- 1996). Here we adoptively transferred immune lympho-
cytes into the CSF to determine whether heterotypic CTLdinates relative to bregma: anterior, 1.0 mm; left lateral,
2.25 mm; depth, 2.5 mm). The next day, 5 1 105 cells were sufficient by themselves to protect against the same
disease. In a heterotypically immune spleen cell popula-were inoculated into the ipsilateral cerebral ventricle in
5 ml as before. Clone 1.3 (6/6 mice), clone 1.8 (5/5 mice), tion, CD8/ CTL were the key protective cell type and
CD4/ T cells made no significant contribution to eitherand heterotypically immune spleen cells (6/6 mice) all
protected against parenchymal virus infection, whereas in vitro restimulation or in vivo anti-viral immunity. In a
homotypically immune population, either CD8/ CTL ormice given no cells all died (n  10). Thus CTL in the
CSF protected against virus infection in the brain paren- restimulated viral subtype-specific memory B cells were
protective. These two effector cell types clearly func-chyma. Homotypically immune C57BL/10 spleen cells in-
oculated into the CSF protected both C57BL/10 (6/6) and tioned synergistically in combatting intracerebral A/WSN
infection (Tables 5 and 6). Thus despite the particularC57BL/10.A (6/6) mice against parenchymal virus infec-
tion, implying that antibody-secreting cells in the CSF immunological characteristics of the brain, such as a
paucity of MHC expression and apoptosis-resistant tar-could also be effective against infection in a distant intra-
cerebral site. get cells, the important anti-viral immune effectors were
surprisingly similar to those identified in respiratory influ-The use of a small intracerebral inoculation volume (1
ml) also allowed us to limit the adoptively transferred enza virus infection. Whether the same mechanisms of
anti-viral immunity are employed by these cell popula-cells to a precise site. CTL (105 clone 1.8 cells) inoculated
into the lateral cerebral ventricle protected against tions in the brain as in the lung remains to be determined.
A/WSN infection in either the ipsilateral (5/6 mice sur-
Protection against encephalitis by intracerebralvived) or the contralateral (4/5 mice survived) anterior
CD8/ CTLcaudoputamen or the contralateral cerebral ventricle (5/
5 mice survived). In contrast, 105 clone 1.8 cells inocu- T cells activated in vitro may migrate abnormally in
lated into the brain parenchyma (anterior caudoputamen) vivo (Ford, 1975; Dailey et al., 1982) and survive only
protected if given in the same site as the virus (3/5 mice poorly after adoptive transfer (Sprent, 1976). Consistent
survived), but not if inoculated in the contralateral side (0/ with previous results (Baezinger et al., 1986; Stohlman
5 mice survived). Thus a CTL clone in the CSF protected et al., 1995), we found intracerebral transfer to be a more
against virus infection in all intracerebral sites tested, but effective means of targetting CTL to the brain than intra-
in the brain parenchyma protected only against infection venous. The failure of anti-viral CTL given intravenously
localized to the same site. to protect against A/WSN encephalitis contrasted with
the efficacy of such cells in protecting against influenza
virus pneumonia (Yap et al., 1978; Taylor and Askonas,DISCUSSION
1986). This was most likely due to an inefficient traffic of
adoptively transferred CTL to the intracerebral site ofAfter prior intranasal priming, in vivo CD8/ T cell
depletion abrogates heterotypic but not homotypic pro- viral infection; while cells injected into tail vein reach the
lung capillaries directly, they must traverse at least onetection against A/WSN encephalitis (Stevenson et al.,
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capillary bed to reach the brain and would thus be sus- Protection against A/WSN encephalitis by B cells
ceptible to nonspecific trapping in other sites (Sprent,
Immunoglobulin is found in the CSF in a variety of1976).
central nervous system pathologies (Johnson, 1982) and
The CSF was a highly effective route of adoptively
a direct protective role has been defined for neutralizing
transferring antigen-specific, MHC-restricted protective
antibodies in viral encephalitis (Doherty and Gerhard,
CTL. It remains to be established whether CTL can mi-
1981; Griffin et al., 1994). Plasma cells are known to enter
grate from the CSF to reach infected cells in the brain
the brain after viral infection (Tyor and Griffin, 1993) and
parenchyma or if they respond to antigens reaching the
the local secretion of immunoglobulin may be an im-
CSF from the parenchyma and then mediate protection
portant aspect of protective immunity. The failure to abol-
against parenchymal virus by a remote mechanism. Inter-
ish homotypic protection by CD8 depletion and the MHC
feron-g secretion, which is an important protective mech-
unrestricted nature of this protection implicated antibody-
anism in other intracerebral virus infections (Kundig et
secreting cells as a major component of homotypic im-
al., 1993; Finke et al., 1995), could potentially mediate
munity after adoptive transfer. Since anti-Ig treatment
widespread anti-viral protection in the brain. All the CTL
after in vitro restimulation did not abolish homotypic pro-
clones used showed evidence of interferon-g mRNA syn-
tection, plasma cells, which do not express surface Ig,
thesis by specific PCR amplification of cDNA (not shown). may have been responsible.
Immune clearance of A/WSN infection from the lung is
associated with T cell-mediated immune pathology
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